Publications by authors named "Boris Freidlin"

Claim this Profile
E
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.
Anna Moseley, Michael LeBlanc, Boris Freidlin, Rory M Shallis, Amer M Zeidan

Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Evaluation of Treatment Combinations in Three-Arm Trials.
Edward L Korn, Carmen J Allegra, Boris Freidlin

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-inferiority trials: tyranny or good governance?
Boris Freidlin, Edward L Korn

Lancet Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-to-One Randomization: Rarely Advisable.
Boris Freidlin, Edward L Korn

JCO Oncol Pract· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.
Chen Hu, Boris Freidlin, Edward L Korn

JCO Oncol Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches.
Megan Othus, Boris Freidlin, Edward L Korn

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of randomized clinical trials with a binary endpoint: Conditional versus unconditional analyses of a two-by-two table.
Edward L Korn, Boris Freidlin

Stat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficiency of Biomarker-Driven Clinical Trial Designs.
Boris Freidlin, Edward L Korn

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN).
Yixuan Zhao, Ying Yuan, Edward L Korn, Boris Freidlin

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease.
Boris Freidlin, Larissa A Korde, Edward L Korn

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience.
Jared C Foster, Edward L Korn, Boris Freidlin, Jeffrey A Moscow

JNCI Cancer Spectr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose optimization during drug development: whether and when to optimize.
Edward L Korn, Jeffrey A Moscow, Boris Freidlin

J Natl Cancer Inst· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa M McShane, Boris Freidlin

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.
Patricia M LoRusso, Boris Freidlin

J Natl Cancer Inst· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmenting randomized clinical trial data with historical control data: Precision medicine applications.
Boris Freidlin, Edward L Korn

J Natl Cancer Inst· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Benefit Scales and Trial Design: Some Statistical Issues.
Edward L Korn, Carmen J Allegra, Boris Freidlin

J Natl Cancer Inst· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
Shaji Kumar, Lawrence Baizer, Natalie S Callander, Sergio A Giralt, Jens Hillengass, Boris Freidlin

Blood Cancer J· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time trends with response-adaptive randomization: The inevitability of inefficiency.
Edward L Korn, Boris Freidlin

Clin Trials· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Problematic Biomarker Trial Design.
Boris Freidlin, Edward L Korn

J Natl Cancer Inst· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Quartagno et al.
Boris Freidlin, Chen Hu, Edward L Korn

Clin Trials· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are restricted mean survival time methods especially useful for noninferiority trials?
Boris Freidlin, Chen Hu, Edward L Korn

Clin Trials· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platform Trials - Beware the Noncomparable Control Group.
Lori E Dodd, Boris Freidlin, Edward L Korn

N Engl J Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.
Jared Foster, Boris Freidlin, E L Korn, Malcolm Smith

ESMO Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to H. Uno et al and B. Huang et al.
Boris Freidlin, Edward L Korn

J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.
Mei-Yin C Polley, Edward L Korn, Boris Freidlin

JCO Precis Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis